Compound: Uridine triacetate
SMILES: O=c1n(ccc([nH]1)=O)[C@@H]2O[C@H](COC(=O)C)[C@H]([C@H]2OC(=O)C)OC(=O)C
InChIKey: AUFUWRKPQLGTGF-FMKGYKFTSA-N
Synonyms: Uridine triacetate, 2',3',5'-Tri-O-acetyluridine, 4105-38-8, Triacetyluridine, Vistonuridine, 2',3',5'-Triacetyluridine, PN401, Tri-O-acetyluridine, Vistogard, PN-401, RG2133, Triacetate d'uridine, RG 2133, Triacetato de uridina, 2WP61F175M, CHEBI:90914, DTXSID40961409, NSC79269, [(2R,3R,4R,5R)-3,4-bis(acetyloxy)-5-(2,4-dioxo-1,2,3,4-tetrahydropyrimidin-1-yl)oxolan-2-yl]methyl acetate, uridini triacetas, ((2R,3R,4R,5R)-3,4-bis(acetyloxy)-5-(2,4-dioxo-1,2,3,4-tetrahydropyrimidin-1-yl)oxolan-2-yl)methyl acetate, RefChem:901472, A16AX13, DTXCID001380019, 223-881-5, Triacetyl uridine, Xuriden, (2R,3R,4R,5R)-2-(ACETOXYMETHYL)-5-(2,4-DIOXO-3,4-DIHYDROPYRIMIDIN-1(2H)-YL)TETRAHYDROFURAN-3,4-DIYL DIACETATE, Uridine 2',3',5'-triacetate, MFCD00023795, C15H18N2O9, PN 401, RG-2133, [(2R,3R,4R,5R)-3,4-diacetyloxy-5-(2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methyl acetate, UNII-2WP61F175M, Uridinetriacetate, Uridine triacetate [USAN:INN], uridine-triacetate, Vistogard (TN), EINECS 223-881-5, Xuriden (TN), Uridine, 2,3,5-triacetate, MLS006009982, SCHEMBL871011, URIDINE TRIACETATE [MI], CHEMBL2107381, Uridine triacetate (USAN/INN), URIDINE TRIACETATE [INN], URIDINE TRIACETATE [USAN], [(2R,3R,4R,5S)-3,4-Diacetyloxy-5-(2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methyl acetate, CS-D1799, URIDINE TRIACETATE [WHO-DD], EBC-26823, NSC788948, s6484, 2',3',5'-Tri-O-acetyl-D-uridine, AKOS015964563, DB09144, NSC-788948, NT06907, [(2R,3R,4R,5R)-3,4-diacetoxy-5-(2,4-dioxopyrimidin-1-yl)tetrahydrofuran-2-yl]methyl acetate, URIDINE TRIACETATE [ORANGE BOOK], HY-14905, SMR004701034, SY004945, 2',3',5'-Tri-O-acetyluridine, >=98%, 2a(2),3a(2),5a(2)-Tri-O-acetyluridine, NS00047457, D09985, EN300-7359679, BRD-K18323388-001-01-1, Q22075857
Theoretical properties:
molecular_formula: C15H18N2O9
molecular_weight: 370.31 g/mol
exact_mass: 370.10123016 g/mol
formal_charge: 0
hydrogen_bond_donor_count: 1
hydrogen_bond_acceptor_count: 9
rotatable_bond_count: 8
heavy_atom_count: 26
topological_polar_surface_area: 138 Å²
isotope_atom_count: 0
covalently_bonded_unit_count: 1
Physical properties:
Descriptions:
pubchem: Uridine triacetate is an acetate ester that is uracil in which the three hydroxy hydrogens are replaced by acetate group. A prodrug for uridine, it is used for the treatment of hereditary orotic aciduria and for management of fluorouracil toxicity. It has a role as a prodrug, a neuroprotective agent and an orphan drug. It is a member of uridines and an acetate ester.
chebi: An acetate ester that is uracil in which the three hydroxy hydrogens are replaced by acetate group. A prodrug for uridine, it is used for the treatment of hereditary orotic aciduria  and for management of fluorouracil toxicity.
chembl: URIDINE TRIACETATE is a small molecule listed in the ChEMBL database and has reached clinical trial phase 4.0.
wikipedia: Uridine triacetate (INN), formerly known as vistonuridine, is an orally active tri-acetylated prodrug of uridine used:

in the treatment of hereditary orotic aciduria (brand name Xuriden  ZOOR-ə-den);
to treat people following an overdose of chemotherapy drugs 5-fluorouracil (5-FU) or capecitabine regardless of the presence of symptoms, or who exhibit early-onset, severe or life-threatening toxicity affecting the cardiac or central nervous system, and/or early-onset, unusually severe adverse reactions (e.g., gastrointestinal toxicity and/or neutropenia) within 96 hours following the end of fluorouracil or capecitabine administration (brand name Vistogard).
Uridine triacetate was developed, manufactured and distributed by Wellstat Therapeutics. It was granted breakthrough therapy designation by the U.S. Food and Drug Administration (FDA) and approved for use in the United States in 2015.